About Tourmaline Bio Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with ...

瑞士制药巨头诺华制药(NVS.US)周二表示，将以每股48美元的价格收购美国生物制药公司Tourmaline Bio(TRML.US)。这笔交易对Tourmaline Bio的估值为14亿美元。受此消息影响，Tourmaline Bio周二美股收涨近13%。 诺华制药在声明中表示，Tourmaline Bio专注于开发pacibekitug，这是一种 ...

周二，Tourmaline Bio(TRML.US)飙升超57%，创三年新高，报47.62美元。消息面上，诺华同意以约14亿美元的全现金交易收购该公司，Tourmaline的股东将在此交易中每股获得48美元，该公司将成为诺华的间接全资子公司。交易预计将在2025年第四季度完成。 诺华表示，此次 ...

NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve ...

智通财经APP获悉，周二，Tourmaline Bio(TRML.US)飙升超57%，创三年新高，报47.62美元。消息面上，诺华同意以约14亿美元的全现金交易收购该公司，Tourmaline的股东将在此交易中每股获得48美元，该公司将成为诺华的间接全资子公司。交易预计将在2025年第四季度完成。

Tourmaline Bio, Inc.'s share price dropped by 37% after Chugai's Enspryng, an IL-6 blocker, failed to meet expectations in a study on myasthenia gravis. Tourmaline is developing TOUR006, its own IL-6 ...

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease Pacibekitug is a promising ...

Tourmaline Bio, Inc. announced its first quarter 2025 financial results, highlighting its ongoing Phase 2 TRANQUILITY trial which is set to reveal topline data in the second quarter of 2025. The trial ...

Shares of Tourmaline Bio surged in premarket trading on Tuesday after the US-based biotechnology company agreed to be acquired by Swiss pharmaceutical major Novartis for approximately $1.4 billion.

NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients ...

Tourmaline Bio (TRML) has been catching investor attention recently, even without a specific event driving the headlines. Sometimes, stocks start to move or attract renewed interest for reasons that ...

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Tourmaline Bio today. The company’s shares closed last Friday at $23.40. Take advantage of TipRanks Premium at 50% off! Unlock ...